
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4632128/publications.pdf Version: 2024-02-01



TRIVADI CANESAN

#	Article	IF	CITATIONS
1	LASP-1 interacts with ErbB2 in ovarian cancer cells. Biochemical Journal, 2022, 479, 23-38.	3.7	1
2	Phosphoproteome of signaling by ErbB2 in ovarian cancer cells. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2022, 1870, 140768.	2.3	3
3	Haploidentical Hematopoietic Stem Cell Transplantation in Leukemia's: Experience from a Cancer Center in India. Indian Journal of Hematology and Blood Transfusion, 2021, 37, 463-471.	0.6	6
4	Autologous Stem Cell Transplantation in Testicular Germ Cell Tumor—Preliminary Experience from a Single Center. South Asian Journal of Cancer, 2021, 10, 97-101.	0.6	1
5	Locally Advanced Breast Cancer (LABC): Real-World Outcome of Patients From Cancer Institute, Chennai. JCO Global Oncology, 2021, 7, 767-781.	1.8	15
6	Development and in vitro characterisation of an induced pluripotent stem cell model of ovarian cancer. International Journal of Biochemistry and Cell Biology, 2021, 138, 106051.	2.8	9
7	Development of a Critical Appraisal Tool (AIMRDA) for the Peer-Review of Studies Assessing the Anticancer Activity of Natural Products: A Step towards Reproducibility. Asian Pacific Journal of Cancer Prevention, 2021, 22, 3735-3740.	1.2	1
8	"Hairy Cell Leukemia (HCL): â€~Real World' Outcome― Indian Journal of Hematology and Blood Transfusion, 2020, 36, 267-270.	0.6	0
9	Malnutrition is a predisposing factor for developing recurrent fever following febrile neutropenia in children with acute lymphoblastic leukemia. Pediatric Hematology Oncology Journal, 2020, 5, 75-79.	0.1	3
10	The hedgehog pathway regulates cancer stem cells in serous adenocarcinoma of the ovary. Cellular Oncology (Dordrecht), 2020, 43, 601-616.	4.4	23
11	Olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy–induced vomiting in children: An open″abel, randomized phase 3 trial. Pediatric Blood and Cancer, 2020, 67, e28532.	1.5	17
12	Expression of cancer stem cell markers CD24, EPHA1 and CD9 and their correlation with clinical outcome in epithelial ovarian tumours. Cancer Biomarkers, 2020, 28, 397-408.	1.7	12
13	Gemcitabine, vinorelbine and dexamethasone: A safe and effective regimen for treatment of relapsed/refractory hodgkin's lymphoma. Leukemia Research, 2019, 84, 106188.	0.8	8
14	Analysis of Human Stem Cell Transcription Factors. Cellular Reprogramming, 2019, 21, 171-180.	0.9	12
15	Cancer stem cells contribute to angiogenesis and lymphangiogenesis in serous adenocarcinoma of the ovary. Angiogenesis, 2019, 22, 441-455.	7.2	19
16	Evaluation of Cytogenetic Abnormalities in Patients with Acute Lymphoblastic Leukemia. Indian Journal of Hematology and Blood Transfusion, 2019, 35, 640-648.	0.6	5
17	Real World Experience of Treating Neuroblastoma: Experience from a Tertiary Cancer Centre in India. Indian Journal of Pediatrics, 2019, 86, 417-426.	0.8	6
18	Analysis of hematopoietic stem cells using a composite approach. International Journal of Biochemistry and Cell Biology, 2019, 109, 82-89.	2.8	2

#	Article	IF	CITATIONS
19	Induced pluripotent stem cells: A new strategy to model human cancer. International Journal of Biochemistry and Cell Biology, 2019, 107, 62-68.	2.8	17
20	Intravenous fosaprepitant for the prevention of chemotherapyâ€induced vomiting in children: A doubleâ€blind, placeboâ€controlled, phase III randomized trial. Pediatric Blood and Cancer, 2019, 66, e27551.	1,5	18
21	Abstract 182: Cancer stem cells and tumor angiogenesis in serous adenocarcinoma of ovary. , 2019, , .		3
22	Abstract 3693: GLIS1 can replace MYC to generate induced pluripotent stem cells from ovarian cancer cells. , 2019, , .		0
23	Efficacy of Single Dose Rasburicase (1.5Âmg) for Prophylaxis and Management of Laboratory Tumor Lysis Syndrome. Indian Journal of Hematology and Blood Transfusion, 2018, 34, 618-622.	0.6	6
24	Evaluation of a polymorphism in MYBPC3 in patients with anthracycline induced cardiotoxicity. Indian Heart Journal, 2018, 70, 319-322.	0.5	5
25	Prevalence of multiâ€drug resistant organisms in stool of paediatric patients with acute leukaemia and correlation with blood culture positivity: A single institution experience. Pediatric Blood and Cancer, 2018, 65, e26740.	1.5	15
26	A systematic understanding of signaling by ErbB2 in cancer using phosphoproteomics. Biochemistry and Cell Biology, 2018, 96, 295-305.	2.0	16
27	Pediatric Nonblastic Non-Hodgkin's Lymphoma: A Perspective from India. Indian Journal of Medical and Paediatric Oncology, 2018, 39, 13-17.	0.2	6
28	Therapeutic antibodies against cancer stem cells: a promising approach. Cancer Immunology, Immunotherapy, 2017, 66, 1383-1398.	4.2	12
29	Expression of a novel endothelial marker, C-type lectin 14A, in epithelial ovarian cancer and its prognostic significance. International Journal of Clinical Oncology, 2017, 22, 107-117.	2.2	14
30	Chemotherapy in carcinoma penis: Experience from a tertiary cancer centre in India. Annals of Oncology, 2017, 28, x83.	1.2	2
31	Short-Course Lenalidomide Plus Low-Dose Dexamethasone in the Treatment of Newly Diagnosed Multiple Myeloma—A Single-Centre Pragmatic Study. Current Oncology, 2017, 24, 361-367.	2.2	1
32	Refractory Choriocarcinoma: Complete Response With Oral Etoposide. Journal of Global Oncology, 2017, 3, 678-679.	0.5	2
33	Molecular mechanism and therapeutic implications of selinexor (KPT-330) in liposarcoma. Oncotarget, 2017, 8, 7521-7532.	1.8	37
34	Long-term outcome of diffuse large B-cell lymphoma: Impact of biosimilar rituximab and radiation. Indian Journal of Cancer, 2017, 54, 430.	0.2	9
35	Abstract 4200: Targeting cancer stem cells in serous ovarian carcinoma using RP6530, a dual PI3k δ/γ inhibitor. , 2017, , .		0
36	Tumour angiogenesis—Origin of blood vessels. International Journal of Cancer, 2016, 139, 729-735.	5.1	102

#	Article	IF	CITATIONS
37	Increasing incidence of multidrug-resistant Gram-negative septicaemia during induction therapy of acuteÂmyeloid leukaemia. Journal of Hospital Infection, 2016, 93, 314-315.	2.9	11
38	Acute Myeloid Leukemia in Children: Experience from Tertiary Cancer Centre in India. Indian Journal of Hematology and Blood Transfusion, 2016, 32, 257-261.	0.6	14
39	Cancer Stem Cells – Are Surface Markers Alone Sufficient?. Current Stem Cell Research and Therapy, 2016, 12, 37-44.	1.3	25
40	Voriconazole is a safe and effective anti-fungal prophylactic agent during induction therapy of acute myeloid leukemia. Indian Journal of Medical and Paediatric Oncology, 2016, 37, 53-58.	0.2	8
41	A novel mathematical approach to predict outcome in adult Hodgkin lymphoma Journal of Clinical Oncology, 2016, 34, e19016-e19016.	1.6	0
42	Phase II study of interim PET–CT-guided response-adapted therapy in advanced Hodgkin's lymphoma. Annals of Oncology, 2015, 26, 1170-1174.	1.2	35
43	Gemcitabine, Vinorelbine and Dexamethasone (GVDexa) As Second-Line Salvage Regimen in Relapsed and Refractory Hodgkin's Lymphoma. Blood, 2015, 126, 3948-3948.	1.4	2
44	Nutritional profile of pediatric cancer patients at Cancer Institute, Chennai. Indian Journal of Cancer, 2015, 52, 207.	0.2	16
45	Acute lymphoblastic leukemia: A single center experience with Berlin, Frankfurt, and Munster-95 protocol. Indian Journal of Medical and Paediatric Oncology, 2015, 36, 261-264.	0.2	23
46	P0011 Paediatric acute myeloid leukaemia experience in a tertiary cancer centre in southern India. European Journal of Cancer, 2014, 50, e12.	2.8	0
47	Transformation of follicular lymphoma to high-grade Burkitt′s like lymphoma and acute lymphoblastic leukemia-L3 type. Indian Journal of Medical and Paediatric Oncology, 2013, 34, 136-137.	0.2	0
48	The tumor suppressor RASSF1A is a novel effector of small G protein Rap1A. Protein and Cell, 2011, 2, 237-249.	11.0	9
49	A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer. British Journal of Cancer, 2010, 102, 1355-1360.	6.4	129
50	Lichen planus associated with imatinib mesylate. Indian Journal of Dermatology, Venereology and Leprology, 2009, 75, 527.	0.6	2
51	The tumour suppressor RASSF1A is a novel substrate of PKC. FEBS Letters, 2008, 582, 2270-2276.	2.8	19
52	A phase II study of low dose thalidomide and dexamethasone in previously untreated multiple myeloma. Journal of Clinical Oncology, 2008, 26, 19520-19520.	1.6	0
53	Role of Lymphangiogenesis in Cancer. Journal of Clinical Oncology, 2007, 25, 4298-4307.	1.6	132
54	RPS6KA2, a putative tumour suppressor gene at 6q27 in sporadic epithelial ovarian cancer. Oncogene, 2007, 26, 683-700.	5.9	92

#	Article	IF	CITATIONS
55	Role of lymphangiogenesis in epithelial ovarian cancer. British Journal of Cancer, 2006, 94, 1650-1657.	6.4	27
56	Pharmacokinetically guided phase I trial of topotecan and etoposide phosphate in recurrent ovarian cancer. British Journal of Cancer, 2005, 93, 60-69.	6.4	5
57	Study of Etanercept, a Tumor Necrosis Factor-Alpha Inhibitor, in Recurrent Ovarian Cancer. Journal of Clinical Oncology, 2005, 23, 5950-5959.	1.6	146
58	Involvement of MINK, a Ste20 Family Kinase, in Ras Oncogene-Induced Growth Arrest in Human Ovarian Surface Epithelial Cells. Molecular Cell, 2005, 20, 673-685.	9.7	96
59	Use of changes in CA125 doubling time to detect activity of cytostatic agents in women relapsing with ovarian carcinoma. Study 1 - tamoxifen. Journal of Clinical Oncology, 2005, 23, 5119-5119.	1.6	0
60	A Phase II Study of Etanercept (Enbrel), a Tumor Necrosis Factor α Inhibitor in Patients with Metastatic Breast Cancer. Clinical Cancer Research, 2004, 10, 6528-6534.	7.0	180
61	A Multicenter Phase I Gene Therapy Clinical Trial Involving Intraperitoneal Administration of E1A-Lipid Complex in Patients with Recurrent Epithelial Ovarian Cancer Overexpressing HER-2/neu Oncogene. Clinical Cancer Research, 2004, 10, 2986-2996.	7.0	76
62	Phase II trial of the antiangiogenic agent IM862 in metastatic renal cell carcinoma. British Journal of Cancer, 2004, 91, 1645-1650.	6.4	20
63	Combination antiangiogenesis therapy with marimastat, captopril and fragmin in patients with advanced cancer. British Journal of Cancer, 2004, 91, 30-36.	6.4	33
64	Tyrosine kinase inhibitors in cancer therapy. Clinical Biochemistry, 2004, 37, 618-635.	1.9	197
65	A randomised trial of carboplatin versus carboplatin and thalidomide in ovarian cancer, with evaluation of potential surrogate markers of angiogenesis. Journal of Clinical Oncology, 2004, 22, 5024-5024.	1.6	0
66	A phase 1 study of tazarotene in adults with advanced cancer. British Journal of Cancer, 2003, 89, 808-815.	6.4	11
67	Comparison of prognostic factors in patients in phase I trials of cytotoxic drugs vs new noncytotoxic agents. British Journal of Cancer, 2003, 89, 1166-1171.	6.4	45
68	Use of Positron Emission Tomography in Pharmacokinetic Studies to Investigate Therapeutic Advantage in a Phase I Study of 120-Hour Intravenous Infusion XR5000. Journal of Clinical Oncology, 2003, 21, 203-210.	1.6	39
69	Tumour suppressor genes in sporadic epithelial ovarian cancer. Reproduction, 2002, 123, 341-353.	2.6	21
70	RYK, a Catalytically Inactive Receptor Tyrosine Kinase, Associates with EphB2 and EphB3 but Does Not Interact with AF-6. Journal of Biological Chemistry, 2002, 277, 23037-23043.	3.4	41
71	Physical and transcript map of the region between D6S264 and D6S149 on chromosome 6q27, the minimal region of allele loss in sporadic epithelial ovarian cancer. Oncogene, 2002, 21, 387-399.	5.9	26
72	Retrospective Study of Management of Uterine Sarcomas at Oxford 1990–1998: Role of Adjuvant Treatment. Clinical Oncology, 2002, 14, 54-61.	1.4	5

#	Article	IF	CITATIONS
73	Phase I and Pharmacokinetic Study of PKC412, an Inhibitor of Protein Kinase C. Journal of Clinical Oncology, 2001, 19, 1485-1492.	1.6	226
74	Motif analysis of HLA class II molecules that determine the HPV associated risk of cervical carcinogenesis. International Journal of Molecular Medicine, 2001, 8, 405-12.	4.0	10
75	Evaluation of the Possible Protective Role of Adeno-Associated Virus Type 2 Infection in HPV-Associated Premalignant Disease of the Cervix. Gynecologic Oncology, 2000, 78, 342-345.	1.4	14
76	Phase II study of the oxygen saturation curve left shifting agent BW12C in combination with the hypoxia activated drug mitomycin C in advanced colorectal cancer. British Journal of Cancer, 2000, 82, 1776-1782.	6.4	4
77	Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazine. British Journal of Cancer, 2000, 82, 1759-1763.	6.4	15
78	Induction of thymidine phosphorylase as a pharmacodynamic end-point in patients with advanced carcinoma treated with 5-fluorouracil, folinic acid and interferon alpha. British Journal of Cancer, 2000, 83, 219-224.	6.4	14
79	Evaluation of toremifene for reversal of multidrug resistance in renal cell cancer patients treated with vinblastine. Cancer Chemotherapy and Pharmacology, 2000, 46, 27-34.	2.3	39
80	Overexpression of H-Ryk in epithelial ovarian cancer: prognostic significance of receptor expression. Clinical Cancer Research, 2000, 6, 3271-81.	7.0	20
81	A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis. Clinical Cancer Research, 2000, 6, 4697-704.	7.0	43
82	Phase I trial of the selective mitochondrial toxin MKT 077 in chemo-resistant solid tumours. Annals of Oncology, 1999, 10, 923-927.	1.2	108
83	A phase II study of the modulation of 5-fluorouracil and folinic acid with high-dose infusional hydroxyurea in metastatic colorectal carcinoma. Annals of Oncology, 1999, 10, 981-983.	1.2	5
84	Functional Analysis of H-Ryk, an Atypical Member of the Receptor Tyrosine Kinase Family. Molecular and Cellular Biology, 1999, 19, 6427-6440.	2.3	66
85	Overexpression of H-Ryk in mouse fibroblasts confers transforming ability in vitro and in vivo: correlation with up-regulation in epithelial ovarian cancer. Cancer Research, 1999, 59, 2265-70.	0.9	15
86	Phase I study of the novel cyclic AMP (cAMP) analogue 8-chloro-cAMP in patients with cancer: toxicity, hormonal, and immunological effects. Clinical Cancer Research, 1999, 5, 1682-9.	7.0	38
87	Cyclophosphamide, methotrexate and infusional 5-fluorouracil (infusional CMF) in metastatic breast cancer. British Journal of Cancer, 1998, 77, 1950-1956.	6.4	10
88	Chemotherapy for ovarian cancer - a consensus statement on standard practice. British Journal of Cancer, 1998, 78, 1404-1406.	6.4	57
89	A phase II study of bryostatin 1 in metastatic malignant melanoma. British Journal of Cancer, 1998, 78, 1337-1341.	6.4	70
90	Phase I study of the mitomycin C analogue BMS-181174. British Journal of Cancer, 1998, 77, 2020-2027.	6.4	5

#	Article	IF	CITATIONS
91	A phase II study of mitomycin C and oral etoposide for advanced adenocarcinoma of the upper gastrointestinal tract. Annals of Oncology, 1997, 8, 294-296.	1.2	6
92	The roles of the human major histocompatibility complex and human papillomavirus infection in cervical intraepithelial neoplasia and cervical cancer. Clinical Oncology, 1997, 9, 4-13.	1.4	13
93	Molecular approaches to diagnosis and management of ovarian cancer. Cancer and Metastasis Reviews, 1997, 16, 81-107.	5.9	15
94	IMMUNOHISTOCHEMICAL EXPRESSION OF INHIBIN/ACTIVIN SUBUNITS IN EPITHELIAL AND GRANULOSA CELL TUMOURS OF THE OVARY. , 1997, 181, 413-418.		49
95	Analysis of loss of heterozygosity andKRAS2 mutations in ovarian neoplasms: Clinicopathological correlations. , 1997, 18, 75-83.		42
96	An integrated genetic map of Chromosome 6. Mammalian Genome, 1996, 7, 157-159.	2.2	10
97	Susceptibility to human papillomavirus-associated cervical intra-epithelial neoplasia is determined by specific HLA DR-DQ alleles. , 1996, 67, 595-602.		65
98	Allele loss on chromosome arm 6q and fine mapping of the region at 6q27 in epithelial ovarian cancer. , 1996, 15, 223-233.		80
99	The genomic structure of discoidin receptor tyrosine kinase Genome Research, 1996, 6, 620-627.	5.5	28
100	H-RYK, an unusual receptor kinase: isolation and analysis of expression in ovarian cancer. Molecular Medicine, 1996, 2, 189-203.	4.4	10
101	Methyl DNA adducts, DNA repair, and hypoxanthine-guanine phosphoribosyl transferase mutations in peripheral white blood cells from patients with malignant melanoma treated with dacarbazine and hydroxyurea. Clinical Cancer Research, 1996, 2, 303-10.	7.0	14
102	The genetic analysis of ovarian cancer. British Journal of Cancer, 1995, 72, 521-527.	6.4	76
103	Inhibin as a marker for ovarian cancer. British Journal of Cancer, 1995, 71, 1046-1050.	6.4	106
104	<i>AF6</i> gene on chromosome band 6q27 maps distal to the minimal region of deletion in epithelial ovarian cancer. Genes Chromosomes and Cancer, 1995, 14, 220-222.	2.8	9
105	Localization of an epithelial-specific receptor kinase (EDDR1) to chromosome 6q16. Genomics, 1995, 25, 584-587.	2.9	21
106	Association between HLA DQB1 * 03 and cervical intra-epithelial neoplasia. Molecular Medicine, 1995, 1, 161-71.	4.4	7
107	Role of human papillomavirus in determining the HLA associated risk of cervical carcinogenesis Journal of Clinical Pathology, 1994, 47, 1077-1081.	2.0	30
108	Detection of dimeric inhibin throughout the human menstrual cycle by twoâ€site enzyme immunoassay. Clinical Endocrinology, 1994, 40, 717-723.	2.4	385

#	Article	IF	CITATIONS
109	Fluorescence in situ hybridization analysis using cosmid probes to define chromosome 6q abnormalities in ovarian carcinoma cell lines. Cancer Genetics and Cytogenetics, 1994, 77, 99-105.	1.0	18
110	Combination chemotherapy for intermediate and high grade non-Hodgkin's lymphoma. British Journal of Cancer, 1993, 68, 767-774.	6.4	38
111	Patterns of survival in patients with Hodgkin's disease: Long follow up in a single centre. Annals of Oncology, 1993, 4, 385-392.	1.2	35
112	Patterns of survival in patients with advanced Hodgkin's disease (HD) treated in a single centre over 20 years. British Journal of Cancer, 1992, 65, 429-437.	6.4	9
113	Management of stage II Hodgkin's disease: 15 years experience at St. Bartholomew's Hospital. Annals of Oncology, 1992, 3, 349-356.	1.2	2
114	Radiotherapy for stage I Hodgkin's disease: 20 years experience at St Bartholomew's Hospital. British Journal of Cancer, 1990, 62, 314-318.	6.4	26
115	Acute myeloid leukemia in elderly adults. Hematological Oncology, 1990, 8, 13-21.	1.7	34
116	Autoimmune Haemolytic Anaemia Associated with Malignant Peritoneal Mesothelioma. Acta Clinica Belgica, 1989, 44, 199-201.	1.2	10
117	Short-term therapy for acute myelogenous leukemia Journal of Clinical Oncology, 1988, 6, 218-226.	1.6	40
118	Identification of two normal bcr gene products in the cytoplasm. Oncogene, 1988, 3, 561-6.	5.9	16
119	Cytosine arabinoside in the management of recurrent leukaemia. Hematological Oncology, 1987, 5, 65-69.	1.7	6
120	Angio-immunoblastic lymphadenopathy: A clinical, immunological and molecular study. British Journal of Cancer, 1987, 55, 437-442.	6.4	26
121	Novel chimaeric protein expressed in Philadelphia positive acute lymphoblastic leukaemia. Nature, 1987, 329, 851-853.	27.8	101
122	Haematological classification of the chronic myeloid leukaemias. Best Practice and Research: Clinical Haematology, 1987, 1, 887-906.	1.1	61
123	EVA treatment for recurrent or unresponsive Hodgkin's disease. Cancer Chemotherapy and Pharmacology, 1986, 18, 51-53.	2.3	42
124	Treatment of minimal residual disease in poor risk acute lymphoblastic leukaemia with high-dose cytosine arabinoside (ARA-C). Leukemia Research, 1986, 10, 90.	0.8	0
125	Neurotoxicity of High-Dose Cytosine Arabinoside. Progress in Tumor Research, 1985, 29, 177-182.	0.1	9
126	Central nervous system toxicity of high-dose cytosine arabinoside. Seminars in Oncology, 1985, 12, 227-32.	2.2	28

8